The BeST trial: a randomized phase II study of VEGF, RAF Kinase, and mTOR combination targeted therapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST]

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00378703?term=ECOG-E2804&rank=1

2. Intervention

   Sorafenib tosylate

3. Intervention

   Temsirolimus

4. Resource Description

   Overview : Bevacizumab and sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving different combinations of bevacizumab, sorafenib, and temsirolimus may be more effective than bevacizumab alone in treating metastatic kidney cancer. Purpose: This randomized phase II trial is studying different combinations of bevacizumab, temsirolimus, and sorafenib to see how well they work compared with bevacizumab alone in treating patients with metastatic kidney cancer.antineoplastic combined chemotherapy protocols.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   prostate cancer

8. Topic

   kidney cancer

9. Study Population

   Eligible subjects must be at least 18 years old with no primary brain tumor, brain metastases, or other CNS disease. There must have been more than 4 weeks since biological therapy, surgery, or open biopsy was performed and more than 2 weeks since radiation therapy.

10. Funded by

    Cancer Trials Support Unit

11. Phase

    Phase 2 clinical trial

12. Performed by

    Clinical Protocol & Data Management Shared Resource